Enhancement of DNA vaccine potency using conventional aluminum adjuvants

被引:117
作者
Ulmer, JB
DeWitt, CM
Chastain, M
Friedman, A
Donnelly, JJ
McClements, WL
Caulfield, MJ
Bohannon, KE
Volkin, DB
Evans, RK [1 ]
机构
[1] Merck Res Labs, Dept Vaccine Pharmaceut Res, W Point, PA 19486 USA
[2] Merck Res Labs, Dept Virus & Cell Biol, W Point, PA USA
关键词
DNA vaccine; influenza; herpes simplex virus; adjuvant;
D O I
10.1016/S0264-410X(99)00151-6
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The immunogenicity and protective efficacy of DNA vaccines have been amply demonstrated in numerous animal models of infectious disease. However, the feasibility of DNA vaccines for human use is not yet known. Ln order to investigate potential means of increasing the potency of DNA vaccines, conventional adjuvants such as aluminum salts were tested. Coadministration of these adjuvants with DNA vaccines substantially enhanced the ability of these vaccines to induce antibody responses up to 100-fold in mice and guinea pigs, and 5-10-fold in non-human primates. Effective formulations had no demonstrable effect on the levels of antigen expression in situ and consisted of adjuvants that did not form complexes with the plasmid DNA; rather they exerted their effects on antigen after expression in situ. Therefore, the potency of DNA vaccines both in laboratory rodents and in non-human primates can be substantially increased by simple formulation with conventional aluminum adjuvants. (C) 1999 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:18 / 28
页数:11
相关论文
共 38 条
[1]   DIRECT INTRODUCTION OF GENES INTO RATS AND EXPRESSION OF THE GENES [J].
BENVENISTY, N ;
RESHEF, L .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (24) :9551-9555
[2]   DNA immunization against experimental genital herpes simplex virus infection [J].
Bourne, N ;
Stanberry, LR ;
Bernstein, DI ;
Lew, D .
JOURNAL OF INFECTIOUS DISEASES, 1996, 173 (04) :800-807
[3]   Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients [J].
Calarota, S ;
Bratt, G ;
Nordlund, S ;
Hinkula, J ;
Leandersson, AC ;
Sandström, E ;
Wahren, B .
LANCET, 1998, 351 (9112) :1320-1325
[4]   Gene vaccination with naked plasmid DNA: Mechanism of CTL priming [J].
Corr, M ;
Lee, DJ ;
Carson, DA ;
Tighe, H .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 184 (04) :1555-1560
[5]   Adjuvants - A classification and review of their modes of action [J].
Cox, JC ;
Coulter, AR .
VACCINE, 1997, 15 (03) :248-256
[6]   Characterization of humoral immune responses induced by an influenza hemagglutinin DNA vaccine [J].
Deck, RR ;
DeWitt, CM ;
Donnelly, JJ ;
Liu, MA ;
Ulmer, JB .
VACCINE, 1997, 15 (01) :71-78
[7]   DNA vaccines [J].
Donnelly, JJ ;
Ulmer, JB ;
Shiver, JW ;
Liu, MA .
ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 :617-648
[8]   PRECLINICAL EFFICACY OF A PROTOTYPE DNA VACCINE - ENHANCED PROTECTION AGAINST ANTIGENIC DRIFT IN INFLUENZA-VIRUS [J].
DONNELLY, JJ ;
FRIEDMAN, A ;
MARTINEZ, D ;
MONTGOMERY, DL ;
SHIVER, JW ;
MOTZEL, SL ;
ULMER, JB ;
LIU, MA .
NATURE MEDICINE, 1995, 1 (06) :583-587
[9]  
DONNELLY JJ, 1995, EXPERT OPIN THER PAT, V5, P211
[10]   In vivo absorption of aluminium-containing vaccine adjuvants using Al-26 [J].
Flarend, RE ;
Hem, SL ;
White, JL ;
Elmore, D ;
Suckow, MA ;
Rudy, AC ;
Dandashli, EA .
VACCINE, 1997, 15 (12-13) :1314-1318